Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06291038
NA

Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability

Sponsor: University Hospital, Rouen

View on ClinicalTrials.gov

Summary

Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high. One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test. Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D). The working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.

Official title: Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-10-03

Completion Date

2029-03-01

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks

treatment with glutamine at a dose of 5g 3 times a day for 8 weeks

DIETARY_SUPPLEMENT

• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

Locations (4)

Chu Amiens

Amiens, France

CHU CAEN

Caen, France

Ch Le Havre

Le Havre, France

Chu Rouen

Rouen, France